Key Takeaways
- Volume-led 62% YoY surge, but QoQ margin reset: Revenue grew 71.7% YoY in H1, driven by volume, yet EBITDA margin fell ~300 bps QoQ as freight and energy costs increased and could not be passed through.
- Export shift accelerates: Export share rose to 70% from ~63% in FY26, reflecting stronger international offtake and a deliberate pivot toward higher-value geographies.
- Management draws a hard line at 20% EBITDA: After a quarter that broke the prior ~24% run-rate, the commitment is now firmly "20%+", with any upside described as guesswork given volatile input costs and a deliberate strategy to trade margin for market share.
- Capex cycle is locked in: ₹250 crores committed for FY27 to build two new manufacturing buildings, backed by a soft customer commitment covering ~50% of utilization, with Phase 1 commercialization targeted for Q1 FY28.
- What to watch next quarter: Whether the promised Q3 pass-through of freight and gas costs actually materializes, the pace of utilization ramp beyond 66%, and any stabilization in logistics delays that are stretching lead times to 30–60 days.
Volume & Revenue Growth
- Volume the engine: 62% YoY volume growth powered the 71.7% H1 revenue increase, with higher offtake from existing customers rather than one-off wins doing the heavy lifting.
- Industrial chemicals dominance: The segment contributed ~90% of revenue and remains the core growth driver, supported by a product portfolio that has expanded from 140+ to ~152 products.
- Utilization climbing: Capacity utilization reached 66% in Q2, up from 60% in Q4 FY26, and Q2 surpassed Q1 for the first time despite being a historically softer quarter, signaling genuine demand absorption.
- Pricing partly inflated by cost pass-through: Revenue includes freight cost recovery, and raw material prices rose 10–15% from March to September, so top-line growth partly reflects input inflation passed to customers.
- New customer traction, but details withheld: A couple of marquee large customers were onboarded in the last six months, and management says many new customers are coming on board, though it declined to name or quantify them.
Parag Jhaveri: "Demand is not slowing down. So that's one good sign for us. Demand is growing. We are able to reach out to the either existing customers or new customers with our price band, and we are gaining the business."
Margin: The 300 bps Reset & The New 20% Floor
- The QoQ drop, unpacked: ~200 bps of the ~300 bps EBITDA margin decline came from freight costs doubling to ₹20 crores and gas prices adding ₹1.8 crores, neither of which could be passed on because purchase orders were already locked. The remaining ~100 bps was product mix fluctuation.
- Pass-through promised from Q3: Management expects to recover these spot input cost increases from Q3 FY27 onward, making the Q2 margin hit a timing issue rather than a structural loss.
- The new margin doctrine: The explicit commitment is now 20%+ EBITDA, down from the ~24% run-rate implied in prior quarters. Management calls 20% "the lower side" and says anything above is welcome, but refuses to guide higher, citing input cost volatility and logistics disruption.
- Deleveraging benefit will go to customers, not margin: As utilization rises and fixed costs absorb, management intends to pass the savings to customers to gain market share rather than let margin expand, a deliberate trade-off it frames as "wise" in the current crisis.
- Gross margin improved ~1%: The gross margin uptick from product mix was overwhelmed at the EBITDA line by the freight and energy spike, but the underlying product-level profitability direction is positive.
Parag Jhaveri: "We need to gain more market share in this crisis. So it's better to be wise than foolish to the market despite you have a saving on your deleveraging and you want to increase the margin."
Capex & Capacity: Building for FY28 and Beyond
- ₹250 crores committed for FY27: The spend covers two new manufacturing buildings at the Pakhajan site, funded partly by ₹150 crores of newly sanctioned term loans, and is driven by customer requests for additional quantity from existing relationships plus capacity for newly onboarded marquee customers.
- Phase 1 commercialization by Q1 FY28: Trial production is expected by Q4 FY27, with commercial output starting in Q1 FY28 and utilization ramping to ~75% in FY28 and 80–85% in FY29 for Phase 1.
- Phase 2 (Buildings 3 & 4) earliest by Q4 FY28 or Q1 FY29: Utilization is modeled at 50–60% in the first year, and additional capex will be needed to fill these buildings, with details to be discussed in the January or April call.
- Soft customer commitment de-risks ~50% of utilization: A customer has provided a soft commitment covering roughly half the new capacity, part of a broader localization opportunity as large global lubricant additive players look to source from India.
- FY27 full-year utilization seen at 70%: With 2H expected higher than 1H (~65%) given historical Q3/Q4 strength, the ramp trajectory is intact even if the pace remains gradual.
Export Shift & Competitive Dynamics
- Export share jumped to 70%: Up from ~65% in Q1 FY27 and ~63% in FY26, the mix shift reflects stronger international demand and a deliberate pivot, though the US subsidiary functions only as a stock point.
- Logistics is the biggest operational risk: Vessel unavailability is stretching product delivery times to 30–60 days versus a standard 25–30 days, and freight costs are rising, creating both cost pressure and customer satisfaction risk.
- Customer resistance emerging: Some customers are pushing back on high prices and switching to cheaper suppliers, a fragility that management acknowledges but frames as manageable given its price band competitiveness.
- Market share over margin, explicitly: Management is willing to forgo margin expansion from deleveraging savings to capture share during the current crisis, a stance that prioritizes volume and customer acquisition over near-term profitability.
Supply Agreement & Revenue Visibility
- ₹120 crores received to date under the contract signed last year, with trial production expected by Q4 FY27 and commercialization in Q1 FY28, making it a FY28 growth contributor.
- Revenue target: more than ₹1,600 crores by FY28: Management calls this conservative, preferring to under-promise given current volatility, and clarifies they did not give ₹1,600 crores as an absolute target.
- Longer-term aspiration of $300–400 million in 4–5 years: Management sees no challenge given a $15 billion addressable market, though this is an aspiration rather than a commitment and lacks interim milestones.
- R&D pipeline to fuel growth beyond 2028: Full-fledged R&D is working on new chemistry, with a couple of good results already visible and more expected in six months; management calls R&D "the backbone of the company."
- Several undisclosed contracts in progress: Beyond the one disclosed contract with a financial transaction, the company is working on other contracts without financial implementation that it will not disclose, limiting visibility into the full pipeline.
Parag Jhaveri: "It's better to be conservative than optimistic in today's scenario. We'll be more happy if we cross the target. If you don't cross then we'll ask again question what went wrong."
Balance Sheet & Financial Health
- Debt-to-EBITDA improved sharply: Fell to 2.09x in H1 FY27 from 3.74x in FY26, driven by EBITDA growth and disciplined borrowing, with management expecting to stay well below 2.5x.
- ROE at 27.3%, ROCE at 18.4% for H1 FY27, reflecting the operating leverage benefit as volumes scale and fixed costs absorb.
- Term loans of ₹150 crores sanctioned for the FY27 capex plan, with management indicating it will revisit Board-level debt comfort zones as the capex cycle progresses.
- No backward integration planned as of today, though management says it is always evaluating, keeping the asset-light portion of the model intact for now.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Cost pass-through | Freight and gas cost increases to be passed on to customers | From Q3 FY27 |
| EBITDA margin floor | Maintain above 20%; 20% described as "the lower side" | Ongoing |
| Phase 1 commercialization | Trial production Q4 FY27, commercial output begins | Q1 FY28 |
| Phase 1 utilization ramp | ~75% in FY28, rising to 80–85% in FY29 | FY28–FY29 |
| Phase 2 commercialization | Buildings 3 & 4 operational | Earliest Q4 FY28 or Q1 FY29 |
| Phase 2 first-year utilization | 50–60% | First year post-commissioning |
| FY27 full-year utilization | ~70% | FY27 |
| FY27 capex | ₹250 crores for two new manufacturing buildings | FY27 |
| Revenue target | More than ₹1,600 crores | By FY28 |
| Debt ceiling | Stay well below 2.5x debt-to-EBITDA; Board review to follow | Ongoing |
| R&D investment | Continue investing as needed; "backbone of the company" | Ongoing |
Key Metrics
| Metric | Q2 FY27 |
|---|---|
| Revenue | ₹347.92 cr, +89.5% YoY |
| H1 FY27 revenue | ₹656.98 cr, +71.7% YoY |
| EBITDA | ₹72.92 cr, +118.2% YoY |
| H1 FY27 EBITDA | ₹147.33 cr, +122.8% YoY |
| PAT | ₹33.68 cr vs ₹4.86 cr in Q2 FY26 |
| Volume growth | 62% YoY and 7% QoQ |
| EBITDA margin | ~21% (Q2 FY27), down ~300 bps QoQ; ~200 bps from freight and energy cost, ~100 bps from product mix |
| Capacity utilization | 66%, up from 60% in Q4 FY26 |
| Industrial chemicals revenue share | ~90% of revenue |
| Export revenue share | 70%, up from ~65% in Q1 FY27 and ~63% in FY26 |
| Net working capital cycle | 149 days as of H1 FY27 |
| Total debt | ₹615 cr (short-term ₹329 cr, long-term ₹286 cr) |
| Debt-to-EBITDA ratio | 2.09x in H1 FY27 vs 3.74x in FY26 |
| ROE | 27.3% for H1 FY27 |
| ROCE | 19.1% for H1 FY27 (corrected from 18.4%) |
| Freight cost | ₹20 cr in Q2 FY27, up from ₹10 cr in Q1 FY27 |
| Additional gas cost impact | ₹1.8 cr in Q2 FY27 |
| FY27 planned capex | ₹250 cr, funded by internal accruals of ₹100 cr and term loans of ₹150 cr |
| Supply agreement advances received | ₹120 cr to date; trial production expected Q4 FY27, commercialization Q1 FY28 |
| Product count | 152 products, up from 140+ |
| Raw material price increase | 10–15% overall from March quarter to Q2 FY27 |
| FY27 utilization guidance | 70% (H1 ~65%, implying higher 2H) |
| Phase 1 utilization expectation FY28 | ~75%, rising to 80–85% in FY29 |
| Phase 2 utilization expectation first year | 50–60%, commercializing Q4 FY28 or Q1 FY29 |
| Soft customer commitment for new capex | Covers ~50% of total utilization |
| Addressable market | $15 bn across industrial chemicals including lubricant, rubber, performance chemicals |
| FY28 revenue target | More than ₹1,600 cr, based on pre-war prices |